Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Sub: Intimation - Settlement Agreement

with respect to buprenorphine and naloxone sublingual film

Pursuant to Regulation 30 of Securities and

Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and our past disclosures in this

regard, this is to inform you that the Company has entered into a Settlement Agreement with Indivior Inc. ("Indivior

Inc.") and Indivior UK Limited, ("Indivior UK," and together with Indivior Inc., "Indivior") and

Aquestive Therapeutics, Inc. ("Aquestive"). Pursuant to the agreement, the Company will receive payments totalling

USD 72 million by March 31, 2024. The said agreement resolves all claims between the parties relating to the Company's generic

buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indivior's

and Aquestive's patent infringement allegations and the Company's antitrust counterclaims. As part of the

settlement, the underlying litigation will be dismissed.

This is for your information.

For Dr. Reddy's Laboratories Limited

CC: New York Stock Exchange Inc. (Stock Code :RDY)